Comparison of weekly gluten immunogenic peptide measurement and conventional tools to assess adherence to the gluten-free diet in celiac disease: An observational prospective study
- PMID: 37806557
- DOI: 10.1016/j.ajcnut.2023.10.001
Comparison of weekly gluten immunogenic peptide measurement and conventional tools to assess adherence to the gluten-free diet in celiac disease: An observational prospective study
Abstract
Background: Adherence to the gluten-free diet (GFD) is critical to achieving symptom control and mucosal healing in celiac disease (CeD), but its assessment is difficult.
Objectives: We sought to compare stool gluten immunogenic peptides (GIPs) measurements over a 4-wk period with conventional tools commonly used to monitor compliance with a GFD.
Methods: Consecutive adult patients with CeD attending the Small Bowel Section of the Buenos Aires Gastroenterology Hospital were invited to this observational study and were instructed to collect stool samples on Fridays for 4 consecutive weeks. Weekly mean stool GIP concentration was measured was estimated. GIP results were compared with a self-assessment scale of adherence, specific CeD serology, the celiac symptom index, and the assessment by an expert dietitian.
Results: Fifty-three CeD patients were enrolled and those with stool GIP ≥0.65 μg/g/wk (n = 13; 24.5%) had higher serum concentrations of IgA deamidated gliadin peptides (DGPs) antibodies [69 (29-109) compared with 14 (13-29); P = 0.0005] and IgA tissue transglutaminase [42 (14-200) compared with 10 (7-16); P = 0.02], higher proportion of cases with IgA DGP antibodies >20 AU/mL (84.6% compared with 33.3%; P = 0.002), and a higher self-estimated adherence score [5 (4-9) compared with 9 (7-10); P = 0.003]. GIP did not correlate with celiac symptom index scores (55.6% compared with 30.8%; P = 0.9). Expert dietitian assessment identified 69% [odds ratio (OR): 5.25; 95% CI: 1.1-27.2; P = 0.01] of nonadherent cases when high stool GIP. Logistic regression analysis determined that IgA DGP (adjusted OR: 1.1; 95% CI: 1.01-1.11; P = 0.02) and males (adjusted OR: 28.3; 95% CI: 1.1-722.6; P = 0.04) were independently associated with excessive gluten exposure.
Conclusions: Weekly stool GIP identifies gluten exposure that is not always detected by commonly used GFD adherence assessment methods. The higher the concentration of stool GIP, the better the predictive value of serology and dietitian interviews. Stool GIP is a useful and practical test for GFD monitoring, particularly for risky gluten exposure in real-life scenarios.
Keywords: GIP; antibodies; celiac disease; dietary assessment; gliadin immunogenic peptides; gluten-free diet; treatment.
Copyright © 2023 American Society for Nutrition. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest The authors report no conflicts of interest.
Similar articles
-
Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients.Am J Gastroenterol. 2016 Oct;111(10):1456-1465. doi: 10.1038/ajg.2016.439. Epub 2016 Sep 20. Am J Gastroenterol. 2016. PMID: 27644734 Free PMC article.
-
Real-World Gluten Exposure in Patients With Celiac Disease on Gluten-Free Diets, Determined From Gliadin Immunogenic Peptides in Urine and Fecal Samples.Clin Gastroenterol Hepatol. 2021 Mar;19(3):484-491.e1. doi: 10.1016/j.cgh.2020.03.038. Epub 2020 Mar 23. Clin Gastroenterol Hepatol. 2021. PMID: 32217152
-
Role of Serology, Dietary Assessment, and Fecal Gluten Immunogenic Peptides for Predicting Histologic Recovery in Children with Celiac Disease.Dig Dis Sci. 2023 Feb;68(2):529-540. doi: 10.1007/s10620-022-07762-8. Epub 2022 Dec 2. Dig Dis Sci. 2023. PMID: 36459294
-
Determination of gluten immunogenic peptides for the management of the treatment adherence of celiac disease: A systematic review.World J Gastroenterol. 2021 Oct 7;27(37):6306-6321. doi: 10.3748/wjg.v27.i37.6306. World J Gastroenterol. 2021. PMID: 34712034 Free PMC article.
-
Update on celiac disease.Curr Opin Pediatr. 2020 Oct;32(5):654-660. doi: 10.1097/MOP.0000000000000936. Curr Opin Pediatr. 2020. PMID: 32833796 Review.
Cited by
-
Emerging Pharmaceutical Therapies to Address the Inadequacy of a Gluten-Free Diet for Celiac Disease.Pharmaceuticals (Basel). 2023 Dec 20;17(1):4. doi: 10.3390/ph17010004. Pharmaceuticals (Basel). 2023. PMID: 38275990 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous